Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Declines By 52.9%

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 58,600 shares, a drop of 52.9% from the January 31st total of 124,500 shares. Based on an average daily volume of 2,240,000 shares, the short-interest ratio is presently 0.0 days. Currently, 5.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Invst LLC increased its holdings in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,400 shares of the company’s stock after acquiring an additional 7,200 shares during the quarter. Invst LLC owned approximately 4.31% of Evaxion Biotech A/S worth $43,000 at the end of the most recent quarter. Institutional investors own 11.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Lake Street Capital reduced their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Thursday, February 20th.

Evaxion Biotech A/S Stock Performance

EVAX traded down $0.16 on Friday, hitting $1.94. 165,833 shares of the company’s stock were exchanged, compared to its average volume of 3,639,702. The firm has a market cap of $2.28 million, a PE ratio of -1.34 and a beta of -0.28. Evaxion Biotech A/S has a twelve month low of $1.89 and a twelve month high of $22.05. The stock has a fifty day moving average of $3.40 and a two-hundred day moving average of $9.23. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.